Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]AZD5718 in Healthy Male Volunteers
NCT03948451Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atuliflapon in cardiovascular disease (CVD), sponsored by AstraZeneca. Primary endpoints: Amount of Drug Excreted, Fraction Excreted and 11 more. Started Apr 2019; status: completed.
02
Drugs
atuliflapon
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03948451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03948451.